文献速递泌尿男性生殖肿瘤

[68Ga]Ga-PSMA-11 PET-CT在MRI可疑或高危但非可疑前列腺癌诊断中的3期随机对照试验

Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial.
PubMed 文献 · Lancet Oncol · 2026-06-10

PRIMARY2研究为多中心、非劣效性、3期随机对照试验,纳入660例活检初治、mpMRI PI-RADS 2或3但临床高危的前列腺癌疑似患者。

要点

  • PSMA PET-CT可使49%的高危但MRI非可疑或可疑患者避免前列腺活检。
  • 两组活检后疼痛、血尿、血精发生率相似。

核心结论

  • [68Ga]Ga-PSMA-11 PET-CT有潜力改善临床高危但MRI非可疑或可疑患者的前列腺癌诊断路径。
  • 仍需健康经济学分析及其他PSMA放射性药物验证以确认临床实施和普适性。

研究设计与样本

  • 多中心、非劣效性、3期随机对照试验,在澳大利亚7家医院开展。
  • 纳入660例活检初治、临床怀疑显著前列腺癌、MRI PI-RADS 2或3但临床高危、PSA≤20 ng/mL、临床T2或以下患者。
  • 1:1随机分配至[68Ga]Ga-PSMA-11 PET-CT组(331例)或系统经会阴前列腺活检组(329例),按研究中心分层,区块大小2或4。
  • 共同主要终点为临床显著前列腺癌比例和PET-CT组6个月内避免活检比例,意向性分析。

主要发现

  • 活检后疼痛(21% vs 21%)、血尿(38% vs 43%)、血精(48% vs 45%)两组相似。
  • PI-RADS 2占335例(51%),PI-RADS 3占325例(49%)。

关键数值与推荐

  • 临床显著前列腺癌定义为Gleason评分3+4(≥10% pattern 4)或更高。
  • 非劣效界值10%,避免活检阈值20%。
  • PET-CT阳性(PRIMARY评分3-5)者行PSMA-PET靶向经会阴前列腺活检,阴性(PRIMARY评分1-2)者避免活检。

临床怎么用

  • 对于临床高危但mpMRI PI-RADS 2或3的活检初治患者,可考虑[68Ga]Ga-PSMA-11 PET-CT以减少不必要的活检。
  • PET-CT阳性者行靶向活检,阴性者可安全避免活检而不影响临床显著前列腺癌诊断。

局限性

  • 未收集种族数据。
  • 参与者和研究者未设盲。
  • 随访仍在进行中。
  • 需健康经济学分析及其他PSMA放射性药物验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: MRI is recommended for men with clinical suspicion of significant prostate cancer. Those with high clinical risk but non-suspicious or equivocal MRI often undergo prostate biopsy, but have a low likelihood of clinically significant prostate cancer, and a high incidence of clinically insignificant prostate cancer. We aimed to investigate whether gallium-68 ([68Ga]Ga)-prostate-specific membrane antigen (PSMA)-11 PET-CT could reduce the number of people requiring prostate biopsy and limit biopsy to targeted cores, without compromising clinically significant prostate cancer diagnosis. METHODS: In this multicentre, non-inferiority, phase 3, randomised controlled trial, done at at seven Australian hospitals, we recruited biopsy-naive participants with clinical suspicion of significant prostate cancer, equivocal (Prostate Imaging-Reporting and Data System [PI-RADS] 3) or non-suspicious (PI-RADS 2) MRI but high clinical risk (eg, prostate-specific antigen [PSA] density of >0·1 ng/mL/mL, strong family history of prostate cancer, abnormal digital rectal examination, BRCA mutation, PSA >10 ng/mL, PSA doubling time <36 months, or PSA velocity >0·75 ng/mL per year), PSA of 20 ng/mL or less, and clinical T2 disease or less. Participants were randomly assigned (1:1) using a centralised web-based system to undergo [68Ga]Ga-PSMA-11 PET-CT (experimental group) or systematic transperineal prostate biopsy (control group), using block sizes of two or four and stratification by study site. There was no masking for participants or investigators. Participants with positive [68Ga]Ga-PSMA-11 PET-CT (PRIMARY score 3-5) underwent PSMA-PET-targeted transperineal prostate biopsies, whereas those with a negative result (PRIMARY score 1-2) avoided biopsy. The co-primary outcomes were the proportion of participants with clinically significant prostate cancer, defined as a Gleason score of 3 + 4 (≥10% pattern 4) or higher, and the proportion of participants in the [68Ga]Ga-PSMA-11 PET-CT group who avoided biopsy within 6 months of random assignment. A two-sided 95% Wald CI based on a binomial model was used to estimate the risk difference in the proportion of participants with clinically significant prostate cancer (non-inferiority margin 10%) and to estimate the proportion of participants in the experimental group who had avoided biopsy 6 months after random assignment (20% threshold), analysed based on intention to treat. This trial is registered with ClinicalTrials.gov, NCT05154162, and participant follow-up is ongoing. FINDINGS: Between March 2, 2022, and Aug 24, 2025, 660 eligible male participants were enrolled and had a median age of 61 years (IQR 56-66), a median PSA of 5·2 ng/mL (4·0-7·0), and a median PSA density of 0·13 ng/mL/mL (0·09-0·17). There were PI-RADS 2 in 335 (51%) participants and PI-RADS 3 in 325 (49%) participants. Ethnicity data were not collected. 329 (50%) were assigned to the control group with systematic transperineal prostate biopsy, and 331 (50%) were assigned to the experimental group with [68Ga]Ga-PSMA-11 PET-CT. The proportion of participants with clinically significant prostate cancer in the experimental group (39 [12%] of 331) was non-inferior to the control (51 [16%] of 329; difference -3·7% [95% CI -8·9 to 1·5%]; p=0·0093). Use of [68Ga]Ga-PSMA-11 PET-CT avoided biopsy in 163 (49%) of 331 participants (95% CI 44 to 55%; p <0·0001). After prostate biopsy, participants reported similar proportions of pain (33 [21%] in the experimental group vs 62 [21%] in the control group), haematuria (60 [38%] vs 126 [43%]), and haematospermia (77 [48%] vs 133 [45%]). INTERPRETATION: [68Ga]Ga-PSMA-11 PET-CT could have the potential to improve the diagnostic pathway of patients with a high clinical risk but non-suspicious or equivocal prostate MRI. Further research, including health-economic analyses and validation with other PSMA radiopharmaceuticals, are needed to confirm the clinical implementation and generalisability of this approach. FUNDING: Prostate Cancer Foundation, National Health and Medical Research Council, St Vincent's Curran Foundation, and Peter MacCallum Cancer Foundation.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Buteau JP, Moon D, Fahey MT, et al. Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial. Lancet Oncol. 2026. PMID: 42269655. doi:10.1016/S1470-2045(26)00120-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。